We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
- Authors
Chan, Henry Lik ‐ Yuen; Tsang, Owen Tak ‐ Yin; Hui, Yee ‐ Tak; Fung, James; Lui, Grace Chung ‐ Yan; Lai, Ching ‐ Lung; Wong, Grace Lai ‐ Hung; Chan, Kam ‐ Hon; But, David Yiu ‐ Kuen; Lai, Moon ‐ Sing; Lao, Wai ‐ Cheung; Chan, Carmen Ka ‐ Man; Lam, Yip ‐ Shun; Seto, Wai ‐ Kay; Li, Carlton; Yuen, Man ‐ Fung; Wong, Vincent Wai ‐ Sun
- Abstract
Background and Aim In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12-24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong. Methods We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program. Results Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co-infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty-five (85%) patients received 12-week treatment and six patients received 24-week treatment; 26 (63%) patients received ribavirin combination. Thirty-nine (95%; 95% confidence interval 88.5-100%) patients had undetectable HCV RNA at 12-week post-treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation. Conclusions Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real-life clinical setting in Hong Kong.
- Subjects
RITONAVIR; RIBAVIRIN; CHRONIC hepatitis C; HEPATITIS C virus; LIVER transplantation; THERAPEUTICS
- Publication
Journal of Gastroenterology & Hepatology, 2017, Vol 32, Issue 6, p1230
- ISSN
0815-9319
- Publication type
Article
- DOI
10.1111/jgh.13663